Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 14/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12544178 | 0.99 | TPSAB1 (0.62) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| SCHEMBL2033816 | 0.93 | TPSAB1 (0.64) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| SCHEMBL12642971 | 0.93 | TPSAB1 (0.68) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| SCHEMBL2039427 | 0.92 | TPSAB1 (0.55) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2033817 | 0.92 | TPSAB1 (0.63) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2041445 | 0.92 | TPSAB1 (0.67) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| SCHEMBL12643059 | 0.92 | TPSAB1 (0.65) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2037480 | 0.91 | TPSAB1 (0.64) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| SCHEMBL12643058 | 0.90 | TPSAB1 (0.63) | TPSAB1HRH2CNR1KDM4EALDH1A1 | |
| SCHEMBL12642960 | 0.90 | TPSAB1 (0.56) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | TPSAB1 1/4885HRH2 30/4885CNR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.